Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Seagen Inc.
Mayo Clinic
Corvus Pharmaceuticals, Inc.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Karyopharm Therapeutics Inc
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Taiho Oncology, Inc.
Centre Henri Becquerel
National Institutes of Health Clinical Center (CC)
Pfizer
Seagen Inc.
Children's Hospital Medical Center, Cincinnati
Dana-Farber Cancer Institute
SecuraBio
Incyte Corporation
Chengdu Zenitar Biomedical Technology Co., Ltd
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Haihe Biopharma Co., Ltd.
National Institutes of Health Clinical Center (CC)
Haihe Biopharma Co., Ltd.
Seagen Inc.
Ohio State University Comprehensive Cancer Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Aileron Therapeutics, Inc.
Fudan University
Evopoint Biosciences Inc.
Antengene Corporation
National Institutes of Health Clinical Center (CC)
Sun Yat-sen University
Dizal Pharmaceuticals
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Fudan University
CellCentric Ltd.
Sun Yat-sen University
Columbia University
Ruijin Hospital
Daiichi Sankyo
Fudan University
Fondazione Italiana Linfomi - ETS
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
N.N. Petrov National Medical Research Center of Oncology
Dizal Pharmaceuticals
Baylor College of Medicine
Acrotech Biopharma Inc.
Treeline Biosciences, Inc.
Ruijin Hospital
Kyowa Kirin Co., Ltd.
UNC Lineberger Comprehensive Cancer Center
SciTech Development, Inc.